Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China
· Delayed Price · Currency is CNY 38.75
-0.02 (-0.05%)
At close: Mar 6, 2026
SHA:603014 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 3,626 | 3,535 | 3,454 | 3,294 | 2,778 |
| Other Revenue | 69.49 | 69.49 | 78.52 | 131.76 | 132.56 |
| Revenue | 3,695 | 3,604 | 3,532 | 3,426 | 2,911 |
| Revenue Growth (YoY) | 4.62% | 2.04% | 3.09% | 17.71% | - |
| Cost of Revenue | 2,188 | 2,088 | 1,990 | 1,959 | 1,553 |
| Gross Profit | 1,507 | 1,516 | 1,542 | 1,467 | 1,358 |
| Selling, General & Admin | 781.25 | 801.06 | 857.25 | 884.67 | 841.65 |
| Research & Development | 148.49 | 164.7 | 154.86 | 182.84 | 153.49 |
| Other Operating Expenses | 35.13 | 16.58 | 32.02 | 41.75 | 6.27 |
| Operating Expenses | 975.58 | 1,021 | 1,063 | 1,135 | 1,007 |
| Operating Income | 531.71 | 494.84 | 478.99 | 332.79 | 350.7 |
| Interest Expense | -0.4 | -0.6 | -0.85 | -18.33 | -47.58 |
| Interest & Investment Income | 40.96 | 40.57 | 29.07 | 29.83 | 18.86 |
| Currency Exchange Gain (Loss) | 2.73 | 2.73 | 2.38 | 7.53 | 3.63 |
| Other Non Operating Income (Expenses) | -2.04 | -0.54 | -0.59 | -1.29 | -1 |
| EBT Excluding Unusual Items | 572.96 | 536.99 | 509.01 | 350.53 | 324.6 |
| Gain (Loss) on Sale of Investments | 0.89 | 0.22 | 0.11 | - | 2.18 |
| Gain (Loss) on Sale of Assets | 0.02 | 0.2 | 0.09 | -0.01 | 0.01 |
| Asset Writedown | -3.29 | -2.75 | -3.65 | - | -7.8 |
| Other Unusual Items | 11.02 | 11.02 | 18.25 | 15.32 | 0.31 |
| Pretax Income | 581.6 | 545.68 | 523.81 | 365.84 | 319.3 |
| Income Tax Expense | 107.21 | 96.31 | 81.74 | 50.88 | 59.48 |
| Net Income | 474.39 | 449.37 | 442.07 | 314.96 | 259.82 |
| Net Income to Common | 474.39 | 449.37 | 442.07 | 314.96 | 259.82 |
| Net Income Growth | 7.31% | 1.65% | 40.36% | 21.22% | - |
| Shares Outstanding (Basic) | 392 | 370 | 370 | 364 | 351 |
| Shares Outstanding (Diluted) | 392 | 370 | 370 | 364 | 351 |
| Shares Change (YoY) | 5.96% | - | 1.76% | 3.63% | - |
| EPS (Basic) | 1.21 | 1.21 | 1.19 | 0.87 | 0.74 |
| EPS (Diluted) | 1.21 | 1.21 | 1.19 | 0.87 | 0.74 |
| EPS Growth | 1.32% | 1.68% | 37.47% | 16.98% | - |
| Free Cash Flow | 599.2 | 393 | 55.33 | 447.53 | 103.64 |
| Free Cash Flow Per Share | 1.53 | 1.06 | 0.15 | 1.23 | 0.29 |
| Gross Margin | 40.79% | 42.06% | 43.67% | 42.83% | 46.65% |
| Operating Margin | 14.39% | 13.73% | 13.56% | 9.71% | 12.05% |
| Profit Margin | 12.84% | 12.47% | 12.52% | 9.19% | 8.93% |
| Free Cash Flow Margin | 16.21% | 10.90% | 1.57% | 13.06% | 3.56% |
| EBITDA | 764.25 | 726.82 | 710.24 | 565.73 | 542.22 |
| EBITDA Margin | 20.68% | 20.17% | 20.11% | 16.51% | 18.63% |
| D&A For EBITDA | 232.54 | 231.99 | 231.25 | 232.94 | 191.52 |
| EBIT | 531.71 | 494.84 | 478.99 | 332.79 | 350.7 |
| EBIT Margin | 14.39% | 13.73% | 13.56% | 9.71% | 12.05% |
| Effective Tax Rate | 18.43% | 17.65% | 15.60% | 13.91% | 18.63% |
| Revenue as Reported | 3,695 | 3,604 | 3,532 | 3,426 | 2,911 |
| Advertising Expenses | - | 24.44 | 36.04 | 46.06 | 33.07 |
Source: S&P Capital IQ. Standard template. Financial Sources.